Ganja liqui-gel medication closer to production

• May 05 2019
• http://www.jamaicaobserver.com/sunday-finance/ganja-liqui-gel-medication-closer-to-production_163859

The medical sciences research company, MMJ International Holdings, based in the United States and Jamaica, has reached an agreement with Thermo Fisher Scientific to manufacture its oral drug product for treating multiple sclerosis (MS) and Huntington's disease (HD).

MMJ International Holdings, under the terms of the agreement, will develop the active pharmaceutical ingredient (API) for drug product MMJ 001 as a liquid-filled gel capsule.

MMJ-001 is derived from the marijuana plant containing tetrahydrocannabinol (THC) and cannabidiol (CBD) as a natural whole plant extract.

“As MMJ International Holdings continues to advance to its clinical trials, ThermoFisher Scientific will be supporting MMJ with the FDA, DEA required development API for MMJ's specialised liquid encapsulation solutions,” said Elio Mariani, executive vice-president of research & development at MMJ.

“Patients will be expected to benefit from cGMP (current Good Manufacturing Practice)-quality therapies in an accessible and efficient format.”

This manufacturing agreement enables the development and future commercialisation of MMJ's novel THC- and CBD cannabinoid-based medicine for therapeutic applications across a broad range of diseases once FDA approved. MMJ International Holdings has been at the forefront of THC, CBD based drug research for the treatment of serious diseases, including MS and HD.

“We firmly believe that our MMJ natural whole plant derived molecules with a unique combination of pharmacological properties will be FDA approved as a safe and effective prescription drug that can be of great benefit in treating patients with MS and HD diseases,” said Duane Boise, CEO of MMJ International Holdings. “This agreement with Thermo Fisher Scientific will help us succeed with our company mission to service the unmet needs of patients suffering from these chronic diseases.”